Qiagen (NYSE:QGEN) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in Qiagen (NYSE:QGEN) by 28.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 150,984 shares of the company’s stock after selling 60,754 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Qiagen were worth $6,238,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. CWM LLC boosted its holdings in Qiagen by 12.0% in the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after purchasing an additional 269 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Qiagen by 66.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after acquiring an additional 283 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Qiagen by 2.2% in the 4th quarter. Eagle Asset Management Inc. now owns 20,338 shares of the company’s stock worth $883,000 after acquiring an additional 430 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Qiagen by 1.0% in the 4th quarter. TD Asset Management Inc now owns 53,531 shares of the company’s stock worth $2,330,000 after acquiring an additional 554 shares during the last quarter. Finally, Riverview Trust Co acquired a new position in shares of Qiagen in the 1st quarter worth approximately $28,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Up 0.1 %

QGEN traded up $0.03 during trading hours on Friday, hitting $45.71. 578,765 shares of the company’s stock were exchanged, compared to its average volume of 1,153,446. Qiagen has a 12-month low of $34.74 and a 12-month high of $47.44. The firm has a 50 day moving average of $43.51 and a 200 day moving average of $43.24. The firm has a market cap of $10.43 billion, a P/E ratio of 30.72, a price-to-earnings-growth ratio of 3.33 and a beta of 0.40. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company had revenue of $496.00 million for the quarter, compared to the consensus estimate of $495.45 million. During the same period in the prior year, the firm posted $0.53 EPS. The company’s quarterly revenue was down .2% compared to the same quarter last year. Analysts predict that Qiagen will post 2.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QGEN has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Thursday, June 27th. Finally, Robert W. Baird upped their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.10.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.